Annals of Surgical Oncology

, Volume 14, Issue 7, pp 2171–2172 | Cite as

An Evolving Role of Perioperative Intraperitoneal Chemotherapy After Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis

Letters to the Editor

Keywords

Intraperitoneal Chemotherapy Peritoneal Recurrence Complete Cytoreduction Early Postoperative Intraperitoneal Chemotherapy Peritoneal Surface Malignancy 

References

  1. 1.
    Elias D, Benizri E, Di Pietrantonio D, et al. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14:509–14PubMedCrossRefGoogle Scholar
  2. 2.
    Elias D, Delperro J-R, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11:518–21PubMedCrossRefGoogle Scholar
  3. 3.
    Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 1993; 72:1631–6PubMedCrossRefGoogle Scholar
  4. 4.
    Verwaal VJ, Zoetmulder FA. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2004; 30:280–5PubMedCrossRefGoogle Scholar
  5. 5.
    Elias D, Sideris L, Pocard M, et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 2004; 15:781–5PubMedCrossRefGoogle Scholar
  6. 6.
    Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10:112–22PubMedCrossRefGoogle Scholar
  7. 7.
    Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:77–9CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  1. 1.Peritoneal Surface Malignancy ProgramWashington Cancer InstituteWashingtonUSA

Personalised recommendations